SHC Sotera Health

Sotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day

Sotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day

CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating highlights and financial results.

To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live webcast of the conference will be accessible at this or via the Investor Relations section of the Company’s website at , along with the accompanying materials. A replay of the webcast will be available on the Company’s website later in the day on November 5th.

Investor Day

Sotera Health will hold its inaugural Investor Day on Wednesday, November 20, 2024 at 12:30 p.m. Eastern Time in New York City with presentations by members of the management team. Attendance at the in-person event is by invitation only. Parties interested in attending in person can send inquiries to .

A live webcast of the event will be accessible at . Virtual participants are encouraged to pre-register at this and log in to the webcast approximately 5-10 minutes prior to the start of the event. A live question-and-answer session will follow management’s prepared remarks. Sotera Health intends to make the investor presentation for the event available concurrently with the start of the event. A replay of the video webcast will be available within 48 hours following the conclusion of the event at .

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at . For developments related to Ethylene Oxide, updates can be found at .

Contacts

Jason Peterson

Vice President Investor Relations & Treasurer, Sotera Health

Kristin Gibbs

Chief Marketing Officer, Sotera Health

Source: Sotera Health Company



EN
22/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sotera Health

 PRESS RELEASE

Sotera Health Announces Second-Quarter 2025 Earnings Release Date

Sotera Health Announces Second-Quarter 2025 Earnings Release Date CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and operati...

 PRESS RELEASE

Sotera Health Reports First-Quarter 2025 Results

Sotera Health Reports First-Quarter 2025 Results Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues ...

 PRESS RELEASE

Sotera Health Announces First-Quarter 2025 Earnings Release Date

Sotera Health Announces First-Quarter 2025 Earnings Release Date CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and operatin...

 PRESS RELEASE

Nelson Labs Launches Innovative Rapid Sterility Testing to Significant...

Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (R...

 PRESS RELEASE

Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provi...

Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook 2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis C...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch